Sylvania Platinum — Strong revenue growth continues

Sylvania Platinum (AIM: SLP)

Last close As at 05/08/2026

GBP0.81

2.40 (3.04%)

Market capitalisation

GBP211m

More on this equity

Research: Metals & Mining

Sylvania Platinum — Strong revenue growth continues

Sylvania Platinum reported record quarterly revenue of US$78.7m in Q326, with healthy 4E platinum group metals (PGMs) production (22,853oz, down 7% on the Q226 record), strong PGM prices and a growing chrome contribution. The company expects to achieve or exceed FY26 4E PGM production guidance, but lowered its chrome production guidance due to further weather-related and other challenges as the Thaba joint venture (JV) ramps up to full production. Q326 saw high cost growth, affected by dollar weakness and higher royalty tax. We have cut our FY26e EPS by 19.6% to 28.3 US cents, largely due to the US$12.3m impairment of exploration assets during H126. Our FY27 and FY28 EPS forecasts have been lifted by 1.5% and 2.5% respectively. Our valuation is unchanged at 195p per share.

Written by

Lord Ashbourne

Director of Content, Mining

Metals and mining

Q326 results

6 May 2026

Price 99.00p
Market cap £256m

US$1.36/£; ZAR16.42/US$

Net cash at end Q326

$63.3m

Shares in issue

258.8m
Free float 90.0%
Code SLP
Primary exchange AIM
Secondary exchange N/A
Price Performance
% 1m 3m 12m
Abs 5.3 (8.8) 120.0
52-week high/low 125.8p 43.7p

Business description

Sylvania Platinum focuses on the re-treatment and recovery of platinum group metals including platinum, palladium and rhodium, mainly from tailings dumps and other surface sources, but also lesser amounts of run-of-mine underground ore from Samancor chrome mines in South Africa.

Next events

Q426 results

July 2026

Analysts

Lord Ashbourne
+44 (0)20 3077 5700
Rene Hochreiter
+44 (0)20 3077 5700
Marius Strydom
+44 (0)20 3077 5700

Sylvania Platinum is a research client of Edison Investment Research Limited

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Year end Revenue ($m) PBT ($m) EPS (¢) DPS (p) P/E (x) Yield (%)
6/25 104.2 27.7 7.73 2.75 17.4 2.8
6/26e 248.1 114.5 28.32 9.01 4.7 9.1
6/27e 393.9 240.4 65.73 12.00 2.0 12.1
6/28e 426.2 262.7 70.88 13.00 1.9 13.1

PGM production remains strong

Following six consecutive quarters of increased production, Sylvania’s 4E PGM output slowed less than expected to 22,853oz in Q326. Plant feed tons rose strongly (up 7%), offset by lower plant recoveries and plant feed grade. We lift our FY26 forecast from 93,000oz to 94,900oz. Chrome production increased from 10,531t in Q226 to 19,030t, but due to post-period weather-related and feed grade challenges, Sylvania lowered FY26 guidance from a range of 60,000t to 90,000t to 50,000t to 55,000t. We have similarly reduced our FY26 forecast and take a more conservative view on FY27, with full production of 200,000t now only forecast for FY28.

Record revenue supports our outlook

Healthy production, including US$4.0m in chrome revenue, together with a 28% increase in the PGM basket price ( US$3,047/oz) resulted in record net revenue of US$78.7m in Q226 (up 44%). Total operating costs grew by 23% in rand terms (on strong plant feed growth and higher royalty tax) and 27% in dollar terms (due to dollar weakness). We cut our FY26 revenue forecast by 3.0% to US$248.1m on lower chrome guidance and a delayed expected pick-up in the PGM basket price, but increase our FY27 revenue forecast by 1.1% to US$393.9m (FY28 by 2.2%) on stronger forecast PGM production and the JV ramp-up being achieved.

FY26 EPS cut, but valuation flat at 195p/share

During H126, Sylvania recognised a US$12.3m impairment loss on its Hacra exploration asset, following a decision not to invest further in the project. We cut our FY26 EPS forecast by 19.6% to 28.3 US cents on the back of the impairment and slightly lower revenue forecasts. Higher production forecasts for FY27 and FY28 result in 1.5% (to 65.7 US cents) and 2.5% (to 70.9 US cents) EPS upgrades. We lift our Sylvania Dump Operations (SDO) valuation by 1.8% to 162.1p/share and our JV valuation by 1.7% to 22.7p. We carry exploration assets at book value (down 20.6% to 10.8p/share) following the impairment. Our total valuation is flat at 195p/share.

Record revenue on healthy production and rising PGM prices

Following six consecutive quarters of increased production, Sylvania’s Q326 4E PGM output slowed by 7.3% to 22,853oz in Q326, which is stronger than the 21,589oz we had expected. The company’s capital expenditure cycle over recent years continues to bear fruit with another 6.5% increase in raw materials treated and a 2.7% increase in PGM plant feed to 379,173t. The period included a higher proportion of lower-grade material treated, which is typical at the start of the calendar year, resulting in 5.3% lower feed grade and 3% lower plant recovery. The company is now expected to at least achieve the upper-end of its FY26 4E PGM guidance of 93,000oz and we have lifted our forecast from 93,000oz to 94,900oz. We have also become somewhat more positive on FY27 and FY28 and forecast SDO 4E PGM production of 92,400oz and 90,100oz respectively, with a further c 14,000oz from the JV. While the JV lifted chrome production by 81% to 19,030t in Q326, it experienced post-period weather-related and feed grade challenges, which is a key focus area. As a result, Sylvania lowered FY26 guidance from 90,000t to a range of 50,000t to 55,000t. We have similarly reduced our FY26 forecast and take a more conservative view on FY27 with full production of 200,000t now only forecast for FY28.

On top of the healthy production in Q326, Sylvania’s PGM basket price increased by 28.3% from US$2,374/oz to US$3,047/oz. This was 12.6% lower than our forecast, with the Iran war resulting in a sell-off in early March 2026. We forecast a largely flat basket price for Q426 before an uptick to a more constructive outlook for FY27 based on an expected increase in demand, particularly from the US as it builds strategic stocks to meet its needs, especially its armaments and military requirements (see our February 2026 update note).

Despite the lower-than-expected PGM basket price, Sylvania delivered record quarterly revenue of US$78.7m (25% ahead of our expectation) due to higher-than-expected by-product revenue (resulting from spikes in iridium and ruthenium prices), a strong pick-up in chrome revenue (to US$4.0m) and a large sales adjustment of US$13.8m. As a result of our flat forecast for the PGM basket price in Q426 (pick-up delayed due to the Iran war) and our lower chrome production forecast (on management guidance), we have cut our FY26 revenue forecast by 3% to US$248.1m. Despite a more conservative view on the JV ramp-up (with full production now only forecast for FY28), our increased SDO PGM production forecasts for FY27 and FY28 have resulted in revenue upgrades of 1.1% in FY27 to US$393.9m and 2.1% in FY28 to US$426.2m.

During Q326 total operating costs rose by 21% in rand terms, affected by strong plant feed growth and higher royalty taxes (on the back of strong revenue growth). Dollar costs rose by 27% to US$23.7m, further affected by currency weakness over the period. SDO cash cost per 4E PGM ounce increased by 16% in rand terms and 22% in dollar terms due to the lower feed grade and plant recovery referred to above. We expect this to improve over the course of the calendar year as access to higher-grade current arisings normalises and reliance on lower-grade open pit and historical dump material reduces. We have increased our FY26 total operating cost forecast by 4% to account for the higher observed plant feed, plant efficiency and currency dynamics.

Capital expenditure moderated further to US$3.5m (vs US$7.3m in Q226) over the quarter and is forecast to peak at US$30m for FY26, down from US$36m on revised company guidance, especially as it relates to tailings and infrastructure investment. The company still expects a meaningful reduction in spend over coming years, with US$9.2m guidance for FY27, of which US$6.4m relates to tailings and infrastructure projects.

During Q326, the cash balance increased by 17% from US$54.0m to US$63.3m, with strong operating cash flow, lower capital expenditure and a dividend provision (interim dividend of 2p/share (c US$6.8m) was paid post-period). The forecast reduction in capital expenditure, combined with healthy forecast cash generation and the commencement of JV-related debt repayments, is very supportive of a strongly growing cash balance over coming years. We expect a progressive dividend policy over coming years (the 2p/share interim dividend vs 0.75p/share in the previous year supports this) as well as the increased potential for windfall dividends.

During H126, Sylvania recognised a US$12.3m impairment loss on its Hacra exploration asset, following a decision not to invest further in the project. This has had an adverse effect on our FY26 EPS forecasts as well as our exploration assets valuation, which is based on the company’s book value.

We have cut our FY26 EPS forecast by 19.6% to 28.3 US cents on the back of the impairment and our slightly lower revenue forecasts. Higher production forecasts for FY27 and FY28 result in 1.5% (to 65.7 US cents) and 2.5% (to 70.9 US cents) EPS upgrades.

We forecast a healthy increase in the dividend from 2.75p/share in FY25 to 9p/share in FY26 and 12p/share in FY27 (increased from 10p/share). We forecast a further increase to 13p/share in FY28. The company launched a US$2.0m share buyback programme during Q326 and we believe there is the potential for further buybacks over time as a mechanism to distribute surplus cash if the current conducive PGM environment continues.

Valuation

We lift our SDO valuation by 1.8% to 162.1p/share and our JV valuation by 1.7% to 22.7p. We carry exploration assets at book value (down 20.6% to 10.8p/share) following the impairment. Our total valuation is flat at 195p/share.

The forward P/E multiple implied by our FY26 EPS estimate is an attractive 8.3x, which falls further to 3.6x and 3.3x based on our EPS forecasts for FY27 and FY28, respectively.

General disclaimer and copyright

This report has been commissioned by Sylvania Platinum and prepared and issued by Edison, in consideration of a fee payable by Sylvania Platinum. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Sylvania Platinum

View All

Latest from the Metals & Mining sector

View All Metals & Mining content

Research: Healthcare

SynAct Pharma — Entering the final stretch ahead of topline data

SynAct Pharma has completed last-patient dosing in its Phase IIb ADVANCE study, marking a key milestone ahead of the company’s most important near-term catalyst: top-line efficacy and safety data expected in June 2026. The ADVANCE trial (n=246) is evaluating lead asset resomelagon in newly diagnosed rheumatoid arthritis (RA) patients with elevated inflammatory burden and severe disease activity, alongside first-line methotrexate therapy. Resomelagon is differentiated by its pro-resolution mechanism, designed to actively resolve inflammation rather than suppress immune function. We believe this supports the asset’s positioning as an earlier-line adjunct capable of reducing glucocorticoid dependence and delaying progression to biologics or janus kinase (JAK) inhibitors, where long-term safety and tolerability concerns remain significant. We expect the Phase IIb readout to inform Phase III planning and support partnering discussions.

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.